세계의 인간성장호르몬(HGH) 시장 : 산업 규모, 점유율, 동향, 성장 기회, 예측, 제품 유형별, 용도별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Human Growth Hormone Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Distribution Channel, By Region and Competition, 2020-2030F
세계의 인간성장호르몬(HGH) 시장은 2024년 62억 1,000만 달러로 평가되었고, 2030년까지 13.29%의 견조한 CAGR로 성장할 것으로 전망됩니다.
제약 및 생명공학 산업에서 빠르게 진화하는 이 분야는 뇌하수체에서 생성되는 중요한 호르몬인 소마토트로핀을 사용하여 성장, 발달 및 신진대사 기능을 지원하는 데 중점을 두고 있습니다. 주요 성장 동력으로는 특히 어린이들 사이에서 성장호르몬 결핍증(GHD)의 유병률 증가와 노화 관련 호르몬 감소를 해결하기 위한 고령 인구의 HGH 치료에 대한 관심 증가가 있습니다. 승인된 의료 용도 외에도 HGH는 잠재적인 노화 방지 및 웰니스 혜택에 대한 연구가 진행되면서 그 수요가 더욱 확대되고 있습니다. 이 시장에는 재조합 인간 성장 호르몬(rhGH)과 바이오시밀러를 포함한 다양한 제품이 있으며, 주사제 제형이 이 부문을 지배하고 있습니다. 전략적 R&D, 규제 승인 및 제약 회사 간의 협력이 시장의 경쟁 환경을 형성하고 있습니다. 그러나 접근성 문제와 높은 치료 비용은 개선 목적의 오프라벨 사용에 대한 윤리적 우려와 함께 여전히 과제로 남아 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모(2024년) |
62억 1,000만 달러 |
| 시장 규모(2030년) |
131억 6,000만 달러 |
| CAGR(2025-2030년) |
13.29% |
| 급성장 부문 |
온라인 약국 |
| 최대 시장 |
북미 |
시장 성장 촉진요인
성장호르몬 결핍증(GHD)의 유병률 증가
주요 시장 과제
높은 비용
주요 시장 동향
바이오시밀러
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 인간성장호르몬 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 제품 유형별(장시간 작용형, 기타)
- 용도별(성장호르몬(GH) 결핍증, 터너 증후군, 특발성 저신장, 프라더-윌리 증후군, 재태주수 대비 과소, 기타)
- 유통 채널별(병원 약국, 소매 약국, 온라인 약국, 전문 약국)
- 지역별(북미, 유럽, 아시아태평양, 남미, 중동 및 아프리카)
- 기업별(2024년)
- 제품 시장 맵
제6장 북미의 인간성장호르몬 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 북미 : 국가별 분석
제7장 유럽의 인간성장호르몬 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 인간성장호르몬 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 인간성장호르몬 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 인간성장호르몬 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 중동 및 아프리카 : 국가별 분석
- 아랍에미리트(UAE)
- 사우디아라비아
- 남아프리카
제11장 시장 역학
제12장 시장 동향 및 발전
제13장 Porter's Five Forces 분석
제14장 PESTEL 분석
제15장 경쟁 구도
- Novo Nordisk A/S
- Eli Lilly and Company
- Pfizer, Inc.
- Sandoz International GmbH(Novartis AG)
- Genentech, Inc.(Roche)
- Merck KGaA
- Ferring Pharmaceuticals
- Ipsen Pharma
- Teva Pharmaceutical Industries, Ltd.
제16장 전략적 제안
제17장 기업 소개와 면책사항
HBR
The Global Human Growth Hormone (HGH) Market was valued at USD 6.21 billion in 2024 and is projected to grow at a robust CAGR of 13.29% through 2030. This rapidly evolving sector within the pharmaceutical and biotechnology industry centers on the use of somatotropin-a crucial hormone produced by the pituitary gland-to support growth, development, and metabolic functions. Key growth drivers include the rising prevalence of growth hormone deficiencies (GHD), especially among children, and increased interest in HGH therapy among the aging population to address age-related hormonal decline. In addition to its approved medical applications, HGH is being explored for its potential anti-aging and wellness benefits, further expanding its demand. The market features a wide range of products, including recombinant human growth hormone (rhGH) and biosimilars, with injectable formulations dominating the segment. Strategic R&D initiatives, regulatory approvals, and collaborations among pharmaceutical companies are shaping the market's competitive landscape. However, accessibility issues and high treatment costs remain challenges, alongside ethical concerns about off-label use for enhancement purposes.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 6.21 Billion |
| Market Size 2030 | USD 13.16 Billion |
| CAGR 2025-2030 | 13.29% |
| Fastest Growing Segment | Online Pharmacy |
| Largest Market | North America |
Key Market Drivers
Increasing Prevalence of Growth Hormone Deficiency (GHD)
The growing incidence of Growth Hormone Deficiency (GHD) remains a primary catalyst for the Human Growth Hormone (HGH) market globally. GHD, caused by inadequate hormone secretion from the pituitary gland, significantly affects growth, especially in children, and impacts overall health in adults. Current estimates suggest that GHD occurs in 1 out of every 4,000 to 10,000 live births, with a substantial number of adult-onset cases recorded annually. Greater awareness and improved diagnostic tools have enabled earlier detection and intervention, enhancing patient outcomes. Contributing factors include poor nutrition, increased stress, genetic disorders, and medical conditions involving the hypothalamic-pituitary axis. As access to healthcare broadens, more individuals are seeking evaluation and treatment for growth-related disorders, spurring pharmaceutical companies to develop long-acting therapies and improve patient compliance. This growing patient population continues to drive demand for HGH treatment solutions worldwide.
Key Market Challenges
High Cost
Cost remains a significant barrier in the Global Human Growth Hormone (HGH) Market. The complex production process of recombinant human growth hormone (rhGH), involving high-end biotechnological methods and rigorous quality standards, contributes to elevated prices. The long duration of therapy, often lasting several years, further increases the financial burden on patients and healthcare systems. Limited insurance coverage in certain regions and insufficient public health resources exacerbate access issues. As a result, many patients are unable to afford or maintain treatment, especially in lower-income markets. Addressing affordability through cost-effective production and pricing strategies is essential to broaden access to life-enhancing HGH therapies.
Key Market Trends
Biosimilars
The growing presence of biosimilars is a transformative trend in the Global Human Growth Hormone (HGH) Market. These are biologic products designed to closely resemble original rhGH therapies in terms of safety, efficacy, and quality, but at a more accessible price point. Biosimilars undergo stringent regulatory scrutiny and clinical testing to ensure comparable performance to reference drugs. Their introduction promotes market competition, helping to reduce treatment costs and improve patient access. As biosimilar adoption expands, particularly in cost-sensitive regions, their role in the market is increasing. Nevertheless, regulatory approval processes, interchangeability protocols, and manufacturing consistency remain key considerations. Overall, biosimilars represent a promising path toward greater affordability and availability of HGH treatments.
Key Market Players
- Novo Nordisk A/S
- Eli Lilly and Company
- Pfizer, Inc.
- Sandoz International GmbH (Novartis AG)
- Genentech, Inc. (Roche)
- Merck KGaA
- Ferring Pharmaceuticals
- Ipsen Pharma
- Teva Pharmaceutical Industries, Ltd.
Report Scope:
In this report, the Global Human Growth Hormone (HGH) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Human Growth Hormone (HGH) Market, By Product:
Human Growth Hormone (HGH) Market, By Application:
- Growth Hormone (GH) Deficiency
- Turner Syndrome
- Idiopathic Short Stature
- Prader-Willi Syndrome
- Small for Gestational Age
- Other
Human Growth Hormone (HGH) Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Specialty Pharmacy
Human Growth Hormone (HGH) Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Human Growth Hormone (HGH) Market.
Available Customizations:
Global Human Growth Hormone (HGH) Market report with the given Market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional Market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Types
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Global Human Growth Hormone Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Product (Long Acting, Others)
- 5.2.2. By Application (Growth Hormone (GH) Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Other)
- 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy)
- 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
- 5.2.5. By Company (2024)
- 5.3. Product Market Map
- 5.3.1. By Product
- 5.3.2. By Application
- 5.3.3. By Distribution Channel
- 5.3.4. By Region
6. North America Human Growth Hormone Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Application
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Human Growth Hormone Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Product
- 6.3.1.2.2. By Application
- 6.3.1.2.3. By Distribution Channel
- 6.3.2. Canada Human Growth Hormone Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Product
- 6.3.2.2.2. By Application
- 6.3.2.2.3. By Distribution Channel
- 6.3.3. Mexico Human Growth Hormone Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Product
- 6.3.3.2.2. By Application
- 6.3.3.2.3. By Distribution Channel
7. Europe Human Growth Hormone Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Application
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Human Growth Hormone Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Product
- 7.3.1.2.2. By Application
- 7.3.1.2.3. By Distribution Channel
- 7.3.2. France Human Growth Hormone Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Product
- 7.3.2.2.2. By Application
- 7.3.2.2.3. By Distribution Channel
- 7.3.3. United Kingdom Human Growth Hormone Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Product
- 7.3.3.2.2. By Application
- 7.3.3.2.3. By Distribution Channel
- 7.3.4. Italy Human Growth Hormone Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Product
- 7.3.4.2.2. By Application
- 7.3.4.2.3. By Distribution Channel
- 7.3.5. Spain Human Growth Hormone Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.3. By Product
- 7.3.5.4. By Application
- 7.3.5.5. By Distribution Channel
8. Asia-Pacific Human Growth Hormone Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Application
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Human Growth Hormone Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Product
- 8.3.1.2.2. By Application
- 8.3.1.2.3. By Distribution Channel
- 8.3.2. Japan Human Growth Hormone Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Product
- 8.3.2.2.2. By Application
- 8.3.2.2.3. By Distribution Channel
- 8.3.3. India Human Growth Hormone Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Product
- 8.3.3.2.2. By Application
- 8.3.3.2.3. By Distribution Channel
- 8.3.4. South Korea Human Growth Hormone Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Product
- 8.3.4.2.2. By Application
- 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Human Growth Hormone Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Product
- 8.3.5.2.2. By Application
- 8.3.5.2.3. By Distribution Channel
9. South America Human Growth Hormone Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Application
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Human Growth Hormone Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Product
- 9.3.1.2.2. By Application
- 9.3.1.2.3. By Distribution Channel
- 9.3.2. Argentina Human Growth Hormone Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Product
- 9.3.2.2.2. By Application
- 9.3.2.2.3. By Distribution Channel
- 9.3.3. Colombia Human Growth Hormone Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Product
- 9.3.3.2.2. By Application
- 9.3.3.2.3. By Distribution Channel
10. Middle East and Africa Human Growth Hormone Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Application
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. UAE Human Growth Hormone Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Product
- 10.3.1.2.2. By Application
- 10.3.1.2.3. By Distribution Channel
- 10.3.2. Saudi Arabia Human Growth Hormone Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Product
- 10.3.2.2.2. By Application
- 10.3.2.2.3. By Distribution Channel
- 10.3.3. South Africa Human Growth Hormone Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Product
- 10.3.3.2.2. By Application
- 10.3.3.2.3. By Distribution Channel
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition
- 12.2. Product Development
- 12.3. Recent Developments
13. Porter's analysis
14. PESTEL analysis
15. Competitive Landscape
- 15.1. Novo Nordisk A/S
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (As Reported)
- 15.1.5. Recent Developments
- 15.2. Eli Lilly and Company
- 15.3. Pfizer, Inc.
- 15.4. Sandoz International GmbH (Novartis AG)
- 15.5. Genentech, Inc. (Roche)
- 15.6. Merck KGaA
- 15.7. Ferring Pharmaceuticals
- 15.8. Ipsen Pharma
- 15.9. Teva Pharmaceutical Industries, Ltd.
16. Strategic Recommendations
17. About Us & Disclaimer
